SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
Tandem Diabetes Care recently received FDA clearance for its Control-IQ+ automated insulin delivery technology to be used during pregnancies complicated by type 1 diabetes, covering both its t:slim X2 ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Results published in NEJM demonstrate significant improvements in time in range ...
The FDA has approved the Control-IQ+ automated insulin delivery system for use in pregnant women with type 1 diabetes, ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated ...
Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by ...
The FDA has approved Tandem Diabetes Care’s Control-IQ+ automated insulin delivery technology for use during pregnancy in people with type 1 diabetes. The clearance, supported by the CIRCUIT trial, ...
FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results